ARS Pharmaceuticals (SPRY) Revenue (2022 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Revenue data on file, last reported at $22.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 184.47% year-over-year to $22.7 million; the trailing twelve-month figure through Mar 2026 stood at $99.0 million (up 1.92% YoY), and the FY2025 full-year result was $84.3 million, down 5.46% from the prior year.
• Revenue declined to $22.7 million in Q1 2026, from $28.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $86.6 million in Q4 2024 to a low of $10000.0 in Q2 2023.
• A 5-year average of $15.2 million and a median of $2.1 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue plunged 97.84% in 2023 and jumped 4900.0% in 2024, its largest moves.
• Tracing SPRY's Revenue over 5 years: stood at $189000.0 in 2022, then plunged by 94.71% to $10000.0 in 2023, then jumped by 865710.0% to $86.6 million in 2024, then sank by 67.56% to $28.1 million in 2025, then decreased by 19.25% to $22.7 million in 2026.
• Business Quant data shows SPRY's Revenue at $22.7 million in Q1 2026, $28.1 million in Q4 2025, and $32.5 million in Q3 2025.